Evidence map›Paper›PMID 40141414›Full record

ArticleInternational journal of molecular sciences2025

A First-in-Class Dual Degrader of Bcl-2/Bcl-xL Reverses HIV Latency and Minimizes Ex Vivo Reservoirs from Patients.

Lin-Chun Chang, Michael T Yin, Gregory M Laird, Kristen D Ritter, Jayesh G Shah, Asim K Debnath

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lin-Chun ChangLaboratory of Molecular Modeling and Drug Design, Lindsey F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA.
Michael T YinDepartment of Medicine, College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY 10032, USA.ORCID 0000-0002-9346-9056
Gregory M LairdAccelevir Diagnostics, Baltimore, MD 21202, USA.
Kristen D RitterAccelevir Diagnostics, Baltimore, MD 21202, USA.
Jayesh G ShahDepartment of Medicine, College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY 10032, USA.
Asim K DebnathLaboratory of Molecular Modeling and Drug Design, Lindsey F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA.ORCID 0000-0003-2761-0506

Funding

Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials UnitUM1AI069470 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAGDALENA ELZBIETA SOBIESZCZYK · 2012 to 2026
$44.8M
Columbia Collaborative HIV/AIDS Clinical Trials UnitU01AI069470 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HAMMER, SCOTT M · 2007 to 2011
$15.4M
Centralized Resource to Accurately Quantify Latent and Expressed HIVReservoirsR24AI143502 · NIAID · ACCELEVIR DIAGNOSTICS, LLC · PI Gregory Michael Laird, Albine Martin · 2025 to 2026
$2.1M
Design of inhibitors targeted to the CD4 binding site on HIV - 1gp120R56AI104416 · NIAID · NEW YORK BLOOD CENTER · PI DEBNATH, ASIM K · 2023 to 2023
$777k
National Institute of Health, USA 2R56AI104416-11A1NIAID NIH HHS R24 AI143502NIAID NIH HHS R56 AI104416NIAID NIH HHS U01 AI069470NIAID NIH HHS UM1 AI069470
6 · The paper itself

Abstract

The persistence of latent HIV-1 proviruses in CD4

Indexed as

Anti-HIV Agentsbcl-X ProteinHIV-1HIV InfectionsProto-Oncogene Proteins c-bcl-2Virus LatencyApoptosisCD4-Positive T-LymphocytesHumansAnti-HIV AgentsBCL2L1 protein, humanBCL2 protein, humanbcl-X ProteinProto-Oncogene Proteins c-bcl-2Bcl-2/Bcl-xLHIV latencyNF-kBnon-canonicalprotein degraderviral reservoirs

Identifiers

PMID40141414
PMCPMC11942780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.